Abstract:Background The well-known fact that avian pathogenic Escherichia coli (APEC) is harder to prevent due to its numerous serogroups has promoted the development of biological immunostimulatory materials as new vaccine candidates in poultry farms. Bacterial outer membrane vesicles (OMVs), known as spherical nanovesicles enriched with various immunostimulants, are naturally secreted by Gram-negative bacteria, and have gained much attention for developing effective vaccine candidates. Recent report has demonstrated that OMVs of APEC O78 can induce protective immunity in chickens. Here, a novel multi-serogroup OMVs (MOMVs) vaccine was developed to achieve cross-protection against APEC infection in broiler chickens. Results In this study, OMVs produced by three APEC strains were isolated, purified and prepared into MOMVs by mixing these three OMVs. By using SDS-PAGE and LC–MS/MS, 159 proteins were identified in MOMVs and the subcellular location and biological functions of 20 most abundant proteins were analyzed. The immunogenicity of MOMVs was evaluated, and the results showed that MOMVs could elicit innate immune responses, including internalization by chicken macrophage and production of immunomodulatory cytokines. Vaccination with MOMVs induced specific broad-spectrum antibodies as well as Th1 and Th17 immune responses. The animal experiment has confirmed that immunization with an appropriate dose of MOMVs could not cause any adverse effect and was able to reduce bacteria loads and pro-inflammatory cytokines production, thus providing effective cross-protection against lethal infections induced by multi-serogroup APEC strains in chickens. Further experiments indicated that, although vesicular proteins were able to induce stronger protective efficiency than lipopolysaccharide, both vesicular proteins and lipopolysaccharide are crucial in MOMVs-mediated protection. Conclusions The multi-serogroup nanovesicles produced by APEC strains will open up a new way for the development of next generation vaccines with low toxicity and broad protection in the treatment and control of APEC infection.

A Facile Approach for Development of a Vaccine Made of Bacterial Double-Layered Membrane Vesicles (Dmvs)

Enhancing antibacterial immunotherapy for bacterial pneumonia via nanovaccines coated with outer membrane vesicles

Fight bacteria with bacteria: Bacterial membrane vesicles as vaccines and delivery nanocarriers against bacterial infections

Bio-inspired Virus-Like Nanovesicle for Effective Vaccination.

A Self-Assembling Nanoparticle: Implications for the Development of Thermostable Vaccine Candidates.

Bacterial membrane vesicles combined with nanoparticles for bacterial vaccines and cancer immunotherapy

Envelope Virus-Mimetic Nanovaccines by Hybridizing Bioengineered Cell Membranes with Bacterial Vesicles

Bacterial protoplast-derived nanovesicles as vaccine delivery system against bacterial infection

Bacterial Membrane Vesicles in Pneumonia: From Mediators of Virulence to Innovative Vaccine Candidates

Generation of Membrane-Derived Nanovesicles by Nitrogen Cavitation for Drug Targeting Delivery and Immunization.

Immune Responses Elicited by Outer Membrane Vesicles of Gram-Negative Bacteria: Important Players in Vaccine Development

Outer Membrane Vesicle Vaccine Platforms

Single-dose of hybrid eukaryotic-prokaryotic nanovesicles to drive a rapid and controllable immune response against Klebsiella pneumoniae induced nosocomial pneumonia

Engineered Bacterial Outer Membrane Vesicles with Lipidated Heterologous Antigen as an Adjuvant-Free Vaccine Platform for Streptococcus suis

Exploiting Bacterial Outer Membrane Vesicles As a Cross-Protective Vaccine Candidate Against Avian Pathogenic Escherichia Coli (APEC)

Outer Membrane Vesicles: An Emerging Vaccine Platform

Potential Usefulness of Streptococcus pneumoniae Extracellular Membrane Vesicles as Antibacterial Vaccines

In Situ Capture of Bacterial Toxins for Antivirulence Vaccination

Proof of Concept in Utilizing the Peptidoglycan Skeleton of Pathogenic Bacteria As Antigen Delivery Platform for Enhanced Immune Response

Cellular Vesicles-Based “All-in-one” Vaccine Platform Triggers Mucosal Immunity Against Respiratory Viruses

An Engineered Outer Membrane-Defective Escherichia Coli Secreting Protective Antigens Against Streptococcus Suis Via the Twin-Arginine Translocation Pathway As a Vaccine